These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1057 related articles for article (PubMed ID: 21898114)
21. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer. Yoshimoto M; Takao S; Hirata M; Okamoto Y; Yamashita S; Kawaguchi Y; Takami M; Furusawa H; Morita S; Abe C; Sakamoto J Cancer Chemother Pharmacol; 2012 Aug; 70(2):331-8. PubMed ID: 22526409 [TBL] [Abstract][Full Text] [Related]
22. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223 [TBL] [Abstract][Full Text] [Related]
23. A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer. Silva O; Lopes G; Morgenzstern D; Lobo C; Doliny P; Santos E; Abdullah S; Gautam U; Reis I; Welsh C; Slingerland J; Hurley J; Gluck S Clin Breast Cancer; 2008 Apr; 8(2):162-7. PubMed ID: 18621613 [TBL] [Abstract][Full Text] [Related]
24. Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study. Tanaka M; Takamatsu Y; Anan K; Ohno S; Nishimura R; Yamamoto Y; Masuda N; Mitsuyama S; Tamura K; Anticancer Drugs; 2010 Apr; 21(4):453-8. PubMed ID: 20075712 [TBL] [Abstract][Full Text] [Related]
25. Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer. Kroep JR; Linn SC; Boven E; Bloemendal HJ; Baas J; Mandjes IA; van den Bosch J; Smit WM; de Graaf H; Schröder CP; Vermeulen GJ; Hop WC; Nortier JW Neth J Med; 2010 Sep; 68(9):371-6. PubMed ID: 20876920 [TBL] [Abstract][Full Text] [Related]
26. All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer. Tawfik H; Rostom Y; Elghazaly H Cancer Chemother Pharmacol; 2013 Apr; 71(4):913-9. PubMed ID: 23344713 [TBL] [Abstract][Full Text] [Related]
27. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417 [TBL] [Abstract][Full Text] [Related]
28. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients. Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N J BUON; 2013; 18(3):585-93. PubMed ID: 24065468 [TBL] [Abstract][Full Text] [Related]
29. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer. Cameron DA; Stein S Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499 [TBL] [Abstract][Full Text] [Related]
30. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733 [TBL] [Abstract][Full Text] [Related]
31. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536 [TBL] [Abstract][Full Text] [Related]
32. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Pivot X; Manikhas A; Żurawski B; Chmielowska E; Karaszewska B; Allerton R; Chan S; Fabi A; Bidoli P; Gori S; Ciruelos E; Dank M; Hornyak L; Margolin S; Nusch A; Parikh R; Nagi F; DeSilvio M; Santillana S; Swaby RF; Semiglazov V J Clin Oncol; 2015 May; 33(14):1564-73. PubMed ID: 25605838 [TBL] [Abstract][Full Text] [Related]
33. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126 [TBL] [Abstract][Full Text] [Related]
34. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418 [TBL] [Abstract][Full Text] [Related]
35. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy. Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123 [TBL] [Abstract][Full Text] [Related]
36. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. Traina TA; Theodoulou M; Feigin K; Patil S; Tan KL; Edwards C; Dugan U; Norton L; Hudis C J Clin Oncol; 2008 Apr; 26(11):1797-802. PubMed ID: 18398145 [TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series. Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641 [TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology. Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Akman T; Coskun U; Sener N; Inanc M; Elkiran ET; Ozdemir NY; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Oksuzoglu B; Urakci Z Breast Cancer; 2014 Nov; 21(6):677-83. PubMed ID: 23335064 [TBL] [Abstract][Full Text] [Related]
39. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807 [TBL] [Abstract][Full Text] [Related]
40. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K Tumori; 2015; 101(4):418-23. PubMed ID: 25953439 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]